Loading...
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
Dearnaley, D Jovic, G Syndikus, I Khoo, V Cowan, Richard A Graham, J Aird, E Bottomley, D Huddart, R Jose, C
Dearnaley, D
Jovic, G
Syndikus, I
Khoo, V
Cowan, Richard A
Graham, J
Aird, E
Bottomley, D
Huddart, R
Jose, C
Citations
Altmetric:
Abstract
The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years of follow-up showed that escalated-dose conformal radiotherapy improved biochemical progression-free survival. Based on the sample size calculation, we planned to analyse overall survival when 190 deaths occurred; this target has now been reached, after a median 10 years of follow-up.
Affiliation
Description
Date
2014-02-25
Publisher
Collections
Keywords
Type
Article
Citation
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. 2014: Lancet Oncol